| scholarly article | Q13442814 |
| P2093 | author name string | Robert Stevens | |
| Michael V Knopp | |||
| Nathan C Hall | |||
| John J Wright | |||
| Lai Wei | |||
| Matthew D Ringel | |||
| Motoyasu Saji | |||
| Richard T Kloos | |||
| Mark King | |||
| Paul E Wakely | |||
| Manisha H Shah | |||
| Michael Grever | |||
| Daria Arbogast | |||
| Jennifer Rittenberry | |||
| Jiachao Liang | |||
| Minden Collamore | |||
| Vasyl V Vasko | |||
| P2860 | cites work | High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma | Q44387406 |
| BRAF mutations in papillary carcinomas of the thyroid | Q44595824 | ||
| Optimal two-stage designs for phase II clinical trials | Q46412217 | ||
| BRAF is a therapeutic target in aggressive thyroid carcinoma. | Q46988427 | ||
| Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints | Q47321006 | ||
| BRAF mutations in an Italian cohort of thyroid cancers | Q53366519 | ||
| BRAF mutations are associated with some histological types of papillary thyroid carcinoma | Q60527136 | ||
| BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC | Q60527142 | ||
| BRAF Mutation in Papillary Thyroid Carcinoma | Q73276150 | ||
| Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? | Q73402040 | ||
| Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation | Q77878102 | ||
| Phase II study of sorafenib in patients with advanced hepatocellular carcinoma | Q80112177 | ||
| Is there room for improvement in adverse event reporting in the era of targeted therapies? | Q80688012 | ||
| Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma | Q83195713 | ||
| Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors | Q24676378 | ||
| RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. | Q27824795 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| MAP kinases and hypoxia in the control of VEGF expression | Q34146289 | ||
| BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas | Q34543110 | ||
| BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer | Q34560988 | ||
| Motesanib diphosphate in progressive differentiated thyroid cancer. | Q34791480 | ||
| The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway | Q34811541 | ||
| VEGF and the quest for tumour angiogenesis factors | Q34932327 | ||
| Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring | Q35109633 | ||
| Angiogenesis in endocrine tumors. | Q35564920 | ||
| Keratoacanthomas associated with sorafenib therapy | Q35608349 | ||
| Vascular endothelial growth factor in thyroid cancers | Q36362664 | ||
| Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study | Q36877022 | ||
| Phase II trial of sorafenib in advanced thyroid cancer | Q37121708 | ||
| Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo | Q40301455 | ||
| Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. | Q40356195 | ||
| Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling | Q40806778 | ||
| p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts | Q41026405 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thyroid cancer | Q826522 |
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 1675-1684 | |
| P577 | publication date | 2009-03-02 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase II trial of sorafenib in metastatic thyroid cancer | |
| P478 | volume | 27 |
| Q30367068 | 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer |
| Q34538390 | A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses |
| Q91659044 | A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer |
| Q36201492 | A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer |
| Q36716739 | A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment |
| Q91924795 | A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine |
| Q35206630 | Activated RET and ROS: two new driver mutations in lung adenocarcinoma |
| Q50656948 | Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice |
| Q38217744 | Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets |
| Q38218442 | Advanced thyroid cancers: new era of treatment |
| Q39364787 | Advances in small molecule therapy for treating metastatic thyroid cancer. |
| Q38305056 | Advances in thyroid cancer treatment: latest evidence and clinical potential |
| Q33632654 | Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer |
| Q37832821 | Alternative Therapeutic Approaches in the Treatment of Primary and Secondary Dedifferentiated and Medullary Thyroid Carcinoma |
| Q33704599 | Alternative medical treatment for radioiodine-refractory thyroid cancers. |
| Q91711400 | Amplicon-Based NGS Panels for Actionable Cancer Target Identification in Follicular Cell-Derived Thyroid Neoplasia |
| Q33988335 | Anaplastic thyroid cancer: multimodal treatment results. |
| Q53644218 | Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets |
| Q38657760 | Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies |
| Q37526750 | Anaplastic thyroid carcinoma: pathogenesis and emerging therapies |
| Q24236743 | Angiogenesis-inhibitors for metastatic thyroid cancer |
| Q42037461 | Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2 |
| Q38672966 | Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective? |
| Q37911744 | Approach to the Thyroid Cancer Patient with Bone Metastases |
| Q36604985 | Association Between (18)F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma |
| Q28248127 | BRAF activates and physically interacts with PAK to regulate cell motility |
| Q38281838 | BRAF inhibitors: experience in thyroid cancer and general review of toxicity |
| Q39586177 | BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. |
| Q36209491 | BRAF mutations in thyroid tumors from an ethnically diverse group |
| Q30458424 | BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies |
| Q34695003 | Biomarkers for anti-angiogenic therapy in cancer. |
| Q48441783 | Brain Metastasis from Follicular Thyroid Carcinoma: Treatment with Sorafenib |
| Q35147564 | Cancer-Induced Bone Pain Sequentially Activates the ERK/MAPK Pathway in Different Cell Types in the Rat Spinal Cord |
| Q35295368 | Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer |
| Q38053451 | Choroidal and Orbital Metastases from Thyroid Cancer |
| Q42174969 | Clinical Outcome, Role of BRAFV600E, and Molecular Pathways in Papillary Thyroid Microcarcinoma: Is It an Indolent Cancer or an Early Stage of Papillary Thyroid Cancer? |
| Q41206203 | Clinical characteristics and follow-up of intracranial metastases from thyroid cancer. |
| Q37404382 | Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer |
| Q37667684 | Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation |
| Q34537957 | Clinical, Safety, and Economic Evidence in Radioactive Iodine–Refractory Differentiated Thyroid Cancer: A Systematic Literature Review |
| Q92768988 | Clinicopathological Features Predict Outcomes in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Real-World Study |
| Q38472945 | Combined therapy with 131I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer |
| Q98613560 | Complete response in anaplastic lymphoma kinase-rearranged oncocytic thyroid cancer: A case report and review of literature |
| Q34554398 | Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials |
| Q54385980 | Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer. |
| Q38823954 | Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer |
| Q57828030 | Current and Future Perspectives in Thyroid Carcinoma Treatment |
| Q33677589 | Current concepts and future directions in differentiated thyroid cancer |
| Q27024484 | Current status and future perspectives in differentiated thyroid cancer |
| Q50911764 | Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap |
| Q34929133 | Development of skin hypopigmentation in a patient with metastatic papillary carcinoma thyroid treated with Sorafenib |
| Q35208442 | Differentiated thyroid cancer with liver metastases: lessons learned from managing a series of 14 patients |
| Q35057314 | Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients |
| Q35864072 | Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease |
| Q37988566 | Differentiated thyroid cancers: a comprehensive review of novel targeted therapies |
| Q40629784 | Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study |
| Q38612008 | Drug safety evaluation of lenvatinib for thyroid cancer. |
| Q37983692 | Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies |
| Q33577870 | Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. |
| Q38843403 | Efficacy of lenvatinib in treating thyroid cancer. |
| Q35023367 | Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. |
| Q44591315 | Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis |
| Q41639995 | Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population |
| Q43885465 | Emerging Therapies in Sight for the Fight against Dedifferentiated Thyroid Cancer |
| Q41837594 | Emerging role of multikinase inhibitors for refractory thyroid cancer |
| Q38675367 | Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine |
| Q35370655 | Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches |
| Q34574985 | Endocrine side effects of broad-acting kinase inhibitors |
| Q94463795 | Evaluation of CYFRA 21.1 as a Dedifferentiation Marker of Advanced Thyroid Cancer |
| Q36813563 | Evaluation of Romidepsin for Clinical Activity and Radioactive Iodine Reuptake in Radioactive Iodine–Refractory Thyroid Carcinoma |
| Q36864736 | Evolving approaches to patients with advanced differentiated thyroid cancer |
| Q38292288 | Exogenous albumin inhibits sorafenib-induced cytotoxicity in human cancer cell lines |
| Q39805119 | Exploring new frontiers in molecular imaging: Emergence of68Ga PET/CT |
| Q38851509 | Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E). |
| Q36565803 | First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case Report |
| Q54580043 | Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. |
| Q90291421 | Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors |
| Q33397349 | GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma. |
| Q90291133 | Genetic alterations in anaplastic thyroid carcinoma and targeted therapies |
| Q38128097 | Genetics and epigenetics of sporadic thyroid cancer |
| Q38231825 | Genomic medicine and targeted therapy for solid tumors |
| Q54382047 | Good Clinical Response to Erlotinib in a Patient With Anaplastic Thyroid Carcinoma Harboring an Epidermal Growth Factor Somatic Mutation, L858R, in Exon 21 |
| Q56554243 | Guidelines for the management of thyroid cancer |
| Q42734821 | Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer |
| Q35099457 | Hypoxia-inducible factor in thyroid carcinoma |
| Q41186044 | IL-12 immunotherapy of Braf(V600E)-induced papillary thyroid cancer in a mouse model |
| Q38996577 | Improved Diagnostic Accuracy Using Arterial Phase CT for Lateral Cervical Lymph Node Metastasis from Papillary Thyroid Cancer. |
| Q27003304 | Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis |
| Q84955608 | Individualization of Therapies for Patients with Advanced Differentiated Thyroid Cancers |
| Q36270115 | Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review |
| Q34758477 | Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies |
| Q33590611 | Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma |
| Q91996944 | KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer |
| Q64106158 | LRG‑1 enhances the migration of thyroid carcinoma cells through promotion of the epithelial‑mesenchymal transition by activating MAPK/p38 signaling |
| Q35744562 | Late Intervention with anti-BRAFV600E Therapy Induces Tumor Regression in an Orthotopic Mouse Model of Human Anaplastic Thyroid Cancer |
| Q33819911 | Lessons from mouse models of thyroid cancer |
| Q33587809 | Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer |
| Q37388452 | MEK inhibition reduces glial scar formation and promotes the recovery of sensorimotor function in rats following spinal cord injury |
| Q83938036 | Management of refractory thyroid cancers |
| Q49888000 | Mechanisms of receptor tyrosine kinase activation in cancer |
| Q38828353 | Mechanisms of tumor cell resistance to the current targeted-therapy agents. |
| Q34975148 | Metastatic Dormancy and Progression in Thyroid Cancer: Targeting Cells in the Metastatic Frontier |
| Q26774734 | Molecular Targeted Therapies of Aggressive Thyroid Cancer |
| Q55564375 | Molecular Therapies in Thyroid Cancer. |
| Q37544168 | Molecular markers of aggressiveness of thyroid cancer |
| Q38010030 | Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2 |
| Q33828409 | Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy |
| Q34329018 | Molecular pathogenesis and mechanisms of thyroid cancer |
| Q34318833 | Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma |
| Q38128286 | Molecularly targeted drugs for the treatment of cancer: oral complications and pathophysiology |
| Q35703167 | Monitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI. |
| Q87319896 | Morphology predicts BRAF (V⁶⁰⁰E) mutation in papillary thyroid carcinoma: an interobserver reproducibility study |
| Q53239478 | Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non‐Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation |
| Q26821959 | Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib |
| Q34660901 | Multikinase inhibitors use in differentiated thyroid carcinoma. |
| Q37921602 | Multikinase inhibitors: a new option for the treatment of thyroid cancer. |
| Q36528466 | New Insight into the Treatment of Advanced Differentiated Thyroid Cancer |
| Q36361115 | New Treatment in Advanced Thyroid Cancer |
| Q37238757 | New developments in the diagnosis and treatment of thyroid cancer |
| Q53826487 | New era for treatment in differentiated thyroid cancer |
| Q38074169 | New molecular targeted therapy and redifferentiation therapy for radioiodine-refractory advanced papillary thyroid carcinoma: literature review |
| Q42734670 | New targeted molecular therapies for dedifferentiated thyroid cancer |
| Q40820078 | New targeted therapies for thyroid cancer |
| Q38192680 | New therapeutic options for advanced forms of thyroid cancer |
| Q35381593 | New therapies for dedifferentiated papillary thyroid cancer |
| Q33864524 | New treatment modalities in advanced thyroid cancer |
| Q37872269 | Novel molecular targeted therapies for refractory thyroid cancer |
| Q38260495 | Novel therapies for thyroid cancer |
| Q89703945 | Novel treatments for anaplastic thyroid carcinoma |
| Q39100644 | Nuclear Molecular and Theranostic Imaging for Differentiated Thyroid Cancer |
| Q38396892 | Optimal differentiated thyroid cancer management in the elderly. |
| Q26863326 | Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions |
| Q33633424 | Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients |
| Q37868156 | Oral complications of targeted cancer therapies: A narrative literature review |
| Q53170205 | Pancreatic Metastasis Arising from a BRAFV600E-Positive Papillary Thyroid Cancer: The Role of Endoscopic Ultrasound-Guided Biopsy and Response to Sorafenib Therapy |
| Q90746146 | Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis |
| Q40922523 | Personalization of targeted therapy in advanced thyroid cancer |
| Q27027491 | Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations |
| Q38089099 | Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer |
| Q37970758 | Pharmacotherapy options for advanced thyroid cancer: a systematic review |
| Q38702274 | Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. |
| Q92588652 | Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer |
| Q35891218 | Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group |
| Q37417441 | Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience |
| Q33728406 | Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort |
| Q37441525 | Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies |
| Q38103961 | Phase I/II RAF kinase inhibitors in cancer therapy |
| Q34714310 | Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation |
| Q27851560 | Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer |
| Q33401136 | Phase II study of sorafenib in patients with relapsed or refractory lymphoma. |
| Q36813603 | Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. |
| Q43424854 | Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis. |
| Q39323181 | Platelet‐derived growth factor receptor‐α promotes lymphatic metastases in papillary thyroid cancer |
| Q37066917 | Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours. |
| Q36791086 | Primary extraosseous Ewing sarcoma of the lung in children |
| Q26999887 | Progress in molecular-based management of differentiated thyroid cancer |
| Q38154631 | Protease-activated receptor 2 signalling pathways: a role in pain processing |
| Q34272887 | Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis |
| Q37211774 | RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma |
| Q28709562 | RET Gene Abnormalities and Thyroid Disease: Who Should be Screened and When |
| Q37979656 | RET TKI: potential role in thyroid cancers. |
| Q33990855 | Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyr |
| Q34985320 | Recent Advances in Molecular Diagnosis of Thyroid Cancer |
| Q54550459 | Refractory thyroid cancers |
| Q38055493 | Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma |
| Q49691982 | Reply to Bazaz and Denning |
| Q40252691 | Response to Sorafenib in a Pediatric Patient with Papillary Thyroid Carcinoma with Diffuse Nodular Pulmonary Disease Requiring Mechanical Ventilation |
| Q44062334 | Response to sorafenib treatment in advanced metastatic thyroid cancer |
| Q35560562 | Results of combined treatment of anaplastic thyroid carcinoma (ATC) |
| Q35076227 | Review: Thyroid cancer: emerging role for targeted therapies |
| Q38103397 | Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis |
| Q33682381 | Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. |
| Q36118305 | SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. |
| Q84706700 | SEOM clinical guidelines for the treatment of thyroid cancer |
| Q37696502 | Safety profile of new anticancer drugs. |
| Q60506436 | Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib |
| Q26752891 | Selective use of sorafenib in the treatment of thyroid cancer |
| Q26764899 | Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications |
| Q38057938 | Signaling pathways in follicular cell-derived thyroid carcinomas |
| Q38118647 | Sorafenib and Thyroid Cancer |
| Q33419286 | Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. |
| Q56504638 | Sorafenib and thyroid cancer |
| Q38326036 | Sorafenib for the treatment of thyroid cancer: an updated review. |
| Q36911934 | Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial |
| Q45012482 | Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. |
| Q37562646 | Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study |
| Q26828884 | Sorafenib in metastatic thyroid cancer: a systematic review |
| Q33620083 | Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial |
| Q33927272 | Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer |
| Q35195766 | Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial |
| Q55053748 | Sorafenib in the treatment of thyroid cancer. |
| Q35603183 | Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status |
| Q47119906 | Sorafenib treatment for papillary thyroid carcinoma with diffuse lung metastases in a child with autism spectrum disorder: a case report. |
| Q54308605 | Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center |
| Q38544841 | Sorafenib: 10 years after the first pivotal trial. |
| Q38368008 | Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma |
| Q27003934 | Spinal metastasis in thyroid cancer |
| Q35583906 | Standard and emerging therapies for metastatic differentiated thyroid cancer |
| Q38883187 | Targeted Therapies in Thyroid Cancer: An Extensive Review of the Literature |
| Q35147151 | Targeted Treatment of Differentiated and Medullary Thyroid Cancer |
| Q37686162 | Targeted molecular therapies in thyroid carcinoma |
| Q37825764 | Targeted therapies and thyroid cancer |
| Q37860132 | Targeted therapies for thyroid tumors. |
| Q39776373 | Targeted therapies in thyroid cancer |
| Q37875081 | Targeted therapy in refractory thyroid cancer: current achievements and limitations |
| Q38107011 | Targeted therapy with kinase inhibitors in aggressive endocrine tumors |
| Q37088201 | Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma |
| Q35744471 | The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAFV600EInhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells |
| Q83537172 | The BRAF V600E Mutation in Papillary Thyroid Carcinoma Is Associated with Glucose Transporter 1 Overexpression |
| Q26795503 | The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer |
| Q33770769 | The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors |
| Q37832818 | The Problem of the Patient with Thyroglobulin Elevation but Negative Iodine Scintigraphy: The TENIS Syndrome |
| Q35988731 | The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells |
| Q38017866 | The Role of External Beam Radiation and Targeted Therapy in Thyroid Cancer |
| Q54999825 | The Role of Targeted Therapies or Nonsurgical Treatment of Thyroid Malignancies: Is Surgery Being Replaced? |
| Q38865611 | The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies |
| Q57828027 | The Use of Sorafenib in the Thyroid Cancer |
| Q36263304 | The discovery and development of sorafenib for the treatment of thyroid cancer |
| Q36508942 | The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. |
| Q39837484 | Thyroid Cancer Recurrence in Patients Clinically Free of Disease with Undetectable or Very Low Serum Thyroglobulin Values |
| Q36111541 | Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies |
| Q34821078 | Thyroid cancer: burden of illness and management of disease |
| Q36328045 | Thyroid cancer: pathogenesis and targeted therapy |
| Q51443344 | Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma. |
| Q84812785 | Treating advanced radioresistant differentiated thyroid cancer |
| Q36037051 | Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer |
| Q48075919 | Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments |
| Q26747168 | Treatment of advanced thyroid cancer with targeted therapies: ten years of experience |
| Q38579925 | Treatment of advanced thyroid cancer: role of molecularly targeted therapies |
| Q38370352 | Treatment of distant metastases from follicular cell-derived thyroid cancer |
| Q26862841 | Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer |
| Q37562871 | Trends and Predictors of Chemotherapy Use among Thyroid Cancer Patients in the National Cancer Database (2004-2013). |
| Q37515966 | Tyrosine kinase gene rearrangements in epithelial malignancies |
| Q53109364 | Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials. |
| Q49592440 | Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice |
| Q36894689 | Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. |
| Q48681403 | Unusual CNS presentation of thyroid cancer |
| Q34310219 | Update on thyroid cancer treatment |
| Q33570056 | Update: the status of clinical trials with kinase inhibitors in thyroid cancer |
| Q38185691 | Vandetanib for the treatment of thyroid cancer: an update |
| Q36251480 | Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis |
| Q91765533 | Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers |
| Q40844396 | pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer. |
Search more.